您当前所在的位置:首页 > 产品中心 > 产品详细信息
151319-34-5 分子结构
点击图片或这里关闭

N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide

ChemBase编号:838
分子式:C17H15N5O
平均质量:305.3339
单一同位素质量:305.12766013
SMILES和InChIs

SMILES:
O=C(N(c1cc(c2n3ncc(c3ncc2)C#N)ccc1)CC)C
Canonical SMILES:
CCN(c1cccc(c1)c1ccnc2n1ncc2C#N)C(=O)C
InChI:
InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
InChIKey:
HUNXMJYCHXQEGX-UHFFFAOYSA-N

引用这个纪录

CBID:838 http://www.chembase.cn/molecule-838.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide
IUPAC传统名
N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide
zaleplon
商标名
Sonata
Zalaplon
别名
N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
Sonata
DEA No. 2781
zaleplon
Zaleplon
CL-284846
N-[3-(3-Cyanopyrazolo-[1,5-a]pyrimidin-7-yl)phenyl)-N-ethylacetamide
Zaleplon
CAS号
151319-34-5
MDL号
MFCD00867990
PubChem SID
46508267
160964301
PubChem CID
5719

数据来源

数据来源

所有数据来源 商品来源 非商品来源

理论计算性质

理论计算性质

JChem ALOGPS 2.1
质子受体 质子供体
LogD (pH = 5.5) 1.534877  LogD (pH = 7.4) 1.5348797 
Log P 1.5348797  摩尔折射率 97.2364 cm3
极化性 33.73101 Å3 极化表面积 74.29 Å2
可自由旋转的化学键 里宾斯基五规则 true 
Log P 2.0  LOG S -3.88 
溶解度 4.03e-02 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
Chloroform expand 查看数据来源
Dichloromethane expand 查看数据来源
DMSO: ~20 mg/mL expand 查看数据来源
H2O: insoluble expand 查看数据来源
Methanol expand 查看数据来源
外观
white solid expand 查看数据来源
White to Off-White Solid expand 查看数据来源
熔点
186-187°C expand 查看数据来源
疏水性(logP)
0.9 expand 查看数据来源
保存条件
Controlled Substance, -20°C Freezer expand 查看数据来源
desiccated expand 查看数据来源
protect from light expand 查看数据来源
欧盟危险性物质标志
刺激性(Irritant) 刺激性(Irritant) (Xi) expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
德国WGK号
3 expand 查看数据来源
危险公开号
36/37/38 expand 查看数据来源
安全公开号
26-36 expand 查看数据来源
GHS危险品标识
GHS07 expand 查看数据来源
GHS警示词
Warning expand 查看数据来源
GHS危险声明
H315-H319-H335 expand 查看数据来源
GHS警示性声明
P261-P305 + P351 + P338 expand 查看数据来源
个人保护装置
dust mask type N95 (US), Eyeshields, Gloves expand 查看数据来源
毒品管制信息
USDEA Schedule IV; psychotrope; regulated under CDSA - not available from Sigma-Aldrich Canada expand 查看数据来源
保存温度
2-8°C expand 查看数据来源
生物活性机理
Benzodiazepine receptor agonist, but lacks Bz-associated side-effects expand 查看数据来源
纯度
≥98% (HPLC) expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
应用领域
Hypnotic expand 查看数据来源
Psychosedative expand 查看数据来源
Sedative expand 查看数据来源
Sedatives expand 查看数据来源
Tranquilizer expand 查看数据来源
Empirical Formula (Hill Notation)
C17H15N5O expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Sigma Aldrich Sigma Aldrich TRC TRC
DrugBank -  DB00962 external link
Item Information
Drug Groups illicit; approved; investigational
Description Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Indication For the treatment of short-term treatment of insomnia in adults.
Pharmacology Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABAA-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors.
Toxicity Side effects include abdominal pain, amnesia, dizziness, drowsiness, eye pain, headache, memory loss, menstrual pain, nausea, sleepiness, tingling, weakness
Affected Organisms
Humans and other mammals
Biotransformation Zaleplon is primarily metabolized by aldehyde oxidase.
Absorption Absorption Zaleplon is rapidly and almost completely absorbed following oral administration.
Half Life Approximately 1 hour
Protein Binding Approximately 60% (in vitro plasma protein binding).
Elimination Zaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism. After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
Distribution * 1.4 L/kg
Clearance * 1 L/h/kg
References
Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. [Pubmed]
Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [Pubmed]
Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Physician. 2007 Aug 15;76(4):517-26. [Pubmed]
Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18. [Pubmed]
Dooley M, Plosker GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 Aug;60(2):413-45. [Pubmed]
Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. [Pubmed]
Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com
Sigma Aldrich -  Z0502 external link
Biochem/physiol Actions
Zaleplon is a non-benzodiazepine agonist at the benzodiazepine site of the GABAA receptor; sedative; hypnotic.
Toronto Research Chemicals -  Z145000 external link
Selective non-benzodiazepine GABAA receptor agonist.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. Pubmed
  • Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. Pubmed
  • Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18. Pubmed
  • Dooley M, Plosker GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 Aug;60(2):413-45. Pubmed
  • Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. Pubmed
  • Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392. Pubmed
  • Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Physician. 2007 Aug 15;76(4):517-26. Pubmed
  • Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993)
  • Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1993)
  • Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1993)
  • Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1993)
  • Heydorn, W.E., et al.:
  • Allen, D. et al., Eur. J. Clin. Pharmacol., 1993, 45, 313, (pharmacol, man)
  • Vanover, K.E. et al., Drug Dev. Res., 1994, 33, 39, (pharmacol)
  • Beer, B. et al., J. Clin. Pharmacol., 1994, 34, 335, (pharmacol)
  • Vanover, K.E. et al., Psychopharmacology, 1994, 115, 289, (pharmacol)
  • Beer, B. et al., CNS Drug Rev., 1997, 3, 207, (rev)
  • Hurst, M. et al., CNS Drugs, 1999, 11, 387-392
  • Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 698
  • Dooley, M. et al., Drugs, 2000, 60, 413-445, (rev)
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle